Fixed Phage's patented technology enables bacteriophages to be covalently attached to a wide variety of substrates; this gives them enhanced stability for use in a variety of applications which address two of the world's major challenges, antibiotic resistance and food supply and sustainability. By attaching specific bacteriophages to fish and animal feeds, we can reduce, augment or even substitute for antibiotics in the food chain. This lets us target both human and animal pathogens, such as E. coli, Listeria, Campylobacter, Salmonella, Streptococcus, Pseudomonas, Flavobacteria and others. We are also developing bacteriophage products to address some of the commercially significant bacterial pathogens of plants including potato and apple crops. As our bonded phage products can be stable for months or even years and are less sensitive to temperature and other environmental factors, they can be effectively shipped and applied in remote rural locations. Our patented technology allows us to bond bacteriophages to the surface of plastic or other packaging. This enables us to prevent the bacterial decay of food crops all the way from the farm to the supermarket shelf and beyond. The FAO estimate that well over 30% of all food is wasted and reducing bacterial wastage will play an important part in food sustainability. Bacteriophages also have many potential human applications when antibiotics fail. Phages are expert microbiome engineers and can specifically alter the bacterial microbiome of the human gut, skin, vagina, lung and other micro-environments. Microbiome engineering has important applications to irritable bowel syndrome, acne, bacterial vaginosis and bacterial lung diseases. Our ability to attach bacteriophages to micro- and nano-particles and to enhance their stability and active life span, can potentially enhance their effectiveness in these applications, whether as part of a probiotic supplement or as encapsulated powders/beads.
View Top Employees from Fixed PhageWebsite | http://www.fixed-phage.com |
Revenue | $2 million |
Employees | 16 (10 on RocketReach) |
Founded | 2010 |
Phone | +44 141 945 5156 |
Technologies |
JavaScript,
HTML,
Twitter
+10 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Pharmaceuticals, Science and Engineering, Other Pharmaceuticals and Biotechnology, Healthcare, Consumer, Health Care |
Web Rank | 30 Million |
Keywords | Phages On The Scin, Fixed-Phage |
Competitors | AmpliPhi Biosciences, Destiny Pharma plc, Eligo Bioscience, Second Genome Inc., SynDevRx, Inc. |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 54171 Companies, NAICS Code 541 Companies, NAICS Code 541713 Companies |
Looking for a particular Fixed Phage employee's phone or email?
The Fixed Phage annual revenue was $2 million in 2024.
David Browning is the CEO of Fixed Phage.
10 people are employed at Fixed Phage.
The NAICS codes for Fixed Phage are [5417, 54, 54171, 541, 541713].
The SIC codes for Fixed Phage are [873, 87].